An AI That Promises to “Solve All Diseases” Is About to Test Its First Human Drugs

In the deep alphabet, Google’s mother company, a secret laboratory, it works on a promise that sounds like science fiction: “To solve all diseases.” The company, Isomorphic laboratories are now preparing to start the first human clinical trial for cancer drugs developed by artificial intelligence.

In the last interview with Fortune, President of the selected laboratories and General Depression Colin Murdoch, confirmed that it was on the eve of this monumental step. One of these suggestions is great for anyone who looks at a destructive disease of a loved one. But because a nation is increasingly careful, it causes a cold question: can we really trust the “black box” algorithm with our lives?

Isomorphic Laboratories Deepmind’s Alphafold, scientists were born from the AI ​​system that surprised the complex 3D form of proteins. To understand why this is a great thing, you should know how the drugs are traditionally done. For decades, the trial and the wrong process was a cruel process. Scientists spend more than 10 years and more than one billion dollars in the market, more than one billion dollars in the market.

Isomorphic laboratories use this, AI, Alphafold 3 uses it to speed it up. AI can predict proteins with surprising accuracy of the intricate 3D of proteins in the human body, which allows scientists to enter the physical laboratory perfectly formed to combat a particular disease, first of all

The company has already signed more billion dollars of dollars with the pharmaceutical giants Novartis and Eli Lilly and won $ 600 million in new finances to conduct human testing, starting with oncology. Word medical utopia. “This financing will further develop our next generation of medicinal design, and with the help of our programs and solving the entire disease with the help of the AI,” CEO Demi Hassabis “in March 2024 in March, the mission of our mission to win Nobel laureate in 2024.

Big Tech begins to determine the medication design that is the owner of your treatment? This is the center of attention in deep eyes regarding the role of AI in our lives. The biggest concern is the “black box” problem: AI responds, but we don’t know how it is always. This raises critical questions:

• Does the alphabet have the next cancer drug as you have your search results?
• Will these AI design treatments be affordable or will only be trapped behind the high patents in the sky that are accessible to the rich?
• Will human test standards continue with a car generated copy of copies?
• If a drug is a medicinal incorrect, who is responsible? AI owner’s company? Programmers? AI himself?

When contacting Gizmodo, a spokesperson for Isomorphic laboratories, “There is nothing more to share the company”. “

AI can revolutionize the medicine. But if not checked, the technology can also repeat the worst parts of the industry: a profit on opacity, monopoly and input. Isomorphic laboratories direct mankind to the point of a monumental rotation. If they were successful, they could suffer more from other inventions of history.

However, to do this, a suspicious community deserves an incredibly unprecedented risk.